Mitoglitazone
- Generic Name
- Mitoglitazone
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18N2O4S
- CAS Number
- 146062-49-9
- Unique Ingredient Identifier
- 29I7RP18RG
- Background
Mitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
- First Posted Date
- 2011-06-16
- Last Posted Date
- 2014-11-18
- Lead Sponsor
- Metabolic Solutions Development Company
- Target Recruit Count
- 29
- Registration Number
- NCT01374438
- Locations
- 🇺🇸
Rush Memorial University Medical Center, Chicago, Illinois, United States
Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients
Phase 2
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2010-04-14
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Metabolic Solutions Development Company
- Target Recruit Count
- 356
- Registration Number
- NCT01103414
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2013-05-03
- Lead Sponsor
- Metabolic Solutions Development Company
- Target Recruit Count
- 86
- Registration Number
- NCT00760578
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath